261 related articles for article (PubMed ID: 37355603)
21. The role of pragmatism in explaining heterogeneity in meta-analyses of randomised trials: a protocol for a cross-sectional methodological review.
Aves T; Allan KS; Lawson D; Nieuwlaat R; Beyene J; Mbuagbaw L
BMJ Open; 2017 Sep; 7(9):e017887. PubMed ID: 28871028
[TBL] [Abstract][Full Text] [Related]
22. How pragmatic are randomized trials of remdesivir and favipiravir for in-hospital treatment of COVID-19: a descriptive methodological review of trial design using the PRECIS-2 framework.
Sharma T; Qamar I; Zwarenstein M
J Clin Epidemiol; 2022 Dec; 152():193-200. PubMed ID: 36265553
[TBL] [Abstract][Full Text] [Related]
23. Designing Trials with Purpose: Pragmatic Clinical Trials of Nonpharmacological Approaches for Pain Management.
Gordon KS; Peduzzi P; Kerns RD
Pain Med; 2020 Dec; 21(Suppl 2):S7-S12. PubMed ID: 33313727
[TBL] [Abstract][Full Text] [Related]
24. A dynamic application of PRECIS-2 to evaluate implementation in a pragmatic, cluster randomized clinical trial in two nursing home systems.
Palmer JA; Mor V; Volandes AE; McCreedy E; Loomer L; Carter P; Dvorchak F; Mitchell SL
Trials; 2018 Aug; 19(1):453. PubMed ID: 30134976
[TBL] [Abstract][Full Text] [Related]
25. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
26. Integrating pragmatic and implementation science randomized clinical trial approaches: a PRagmatic Explanatory Continuum Indicator Summary-2 (PRECIS-2) analysis.
Zatzick D; Palinkas L; Chambers DA; Whiteside L; Moloney K; Engstrom A; Prater L; Russo J; Wang J; Abu K; Iles-Shih M; Bulger E
Trials; 2023 Apr; 24(1):288. PubMed ID: 37085877
[TBL] [Abstract][Full Text] [Related]
27. Articles provided insufficient information to conduct an appropriate retrospective assessment of the pragmatic/explanatory features of medicine trials with the PRECIS-2 tool.
Dal-Ré R
Eur J Clin Pharmacol; 2020 Aug; 76(8):1093-1102. PubMed ID: 32447436
[TBL] [Abstract][Full Text] [Related]
28. Intervention Fidelity in Pain Pragmatic Trials for Nonpharmacologic Pain Management: Nuanced Considerations for Determining PRECIS-2 Flexibility in Delivery and Adherence.
Kerns RD; Davis AF; Fritz JM; Keefe FJ; Peduzzi P; Rhon DI; Taylor SL; Vining R; Yu Q; Zeliadt SB; George SZ
J Pain; 2023 Apr; 24(4):568-574. PubMed ID: 36574858
[TBL] [Abstract][Full Text] [Related]
29. Readiness assessment for pragmatic trials (RAPT): a model to assess the readiness of an intervention for testing in a pragmatic trial.
Baier RR; Jutkowitz E; Mitchell SL; McCreedy E; Mor V
BMC Med Res Methodol; 2019 Jul; 19(1):156. PubMed ID: 31319789
[TBL] [Abstract][Full Text] [Related]
30. Could phase 3 medicine trials be tagged as pragmatic? A case study: The Salford COPD trial.
Dal-Ré R
J Eval Clin Pract; 2018 Feb; 24(1):258-261. PubMed ID: 28685913
[TBL] [Abstract][Full Text] [Related]
31. Pragmatic clinical trial design in emergency medicine: Study considerations and design types.
Gettel CJ; Yiadom MYAB; Bernstein SL; Grudzen CR; Nath B; Li F; Hwang U; Hess EP; Melnick ER
Acad Emerg Med; 2022 Oct; 29(10):1247-1257. PubMed ID: 35475533
[TBL] [Abstract][Full Text] [Related]
32. Pragmatic vs. explanatory: an adaptation of the PRECIS tool helps to judge the applicability of systematic reviews for daily practice.
Koppenaal T; Linmans J; Knottnerus JA; Spigt M
J Clin Epidemiol; 2011 Oct; 64(10):1095-101. PubMed ID: 21474282
[TBL] [Abstract][Full Text] [Related]
33. A comparison of meta-analytic methods for synthesizing evidence from explanatory and pragmatic trials.
Sajobi TT; Li G; Awosoga O; Wang M; Menon BK; Hill MD; Thabane L
Syst Rev; 2018 Jan; 7(1):19. PubMed ID: 29370830
[TBL] [Abstract][Full Text] [Related]
34. How pragmatic are the randomised trials used in recommendations for control of glycosylated haemoglobin levels in type 2 diabetic patients in general practice: an application of the PRECIS II tool.
Ettori-Ajasse I; Tatin E; Forbes G; Eldridge S; Dibao-Dina C
Trials; 2020 Mar; 21(1):281. PubMed ID: 32188470
[TBL] [Abstract][Full Text] [Related]
35. Generalizability of randomized controlled trials in primary health care: Applying the PRECIS-2 tool on published protocols.
Papagiannopoulou E; Laiou E; Tatsi C; Dimakopoulos G; Ntzani EE; Siamopoulos K; Tatsioni A
J Eval Clin Pract; 2023 Mar; 29(2):253-262. PubMed ID: 36072984
[TBL] [Abstract][Full Text] [Related]
36. An analysis of published trials found that current use of pragmatic trial labels is uninformative.
Taljaard M; Nicholls SG; Howie AH; Nix HP; Carroll K; Moon PM; Nightingale NM; Giraudeau B; Hey SP; Eldridge SM; Weijer C; Zwarenstein M
J Clin Epidemiol; 2022 Nov; 151():113-121. PubMed ID: 35987403
[TBL] [Abstract][Full Text] [Related]
37. Randomized controlled trials and neurosurgery: the ideal fit or should alternative methodologies be considered?
Mansouri A; Cooper B; Shin SM; Kondziolka D
J Neurosurg; 2016 Feb; 124(2):558-68. PubMed ID: 26315006
[TBL] [Abstract][Full Text] [Related]
38. Making clinical trials more relevant: improving and validating the PRECIS tool for matching trial design decisions to trial purpose.
Loudon K; Zwarenstein M; Sullivan F; Donnan P; Treweek S
Trials; 2013 Apr; 14():115. PubMed ID: 23782862
[TBL] [Abstract][Full Text] [Related]
39. Use of pragmatic randomized trials in multiple sclerosis: A systematic overview.
Hirt J; Janiaud P; Düblin P; Nicoletti GJ; Dembowska K; Nguyen TVT; Woelfle T; Axfors C; Yaldizli Ö; Granziera C; Kuhle J; Kappos L; Hemkens LG
Mult Scler; 2024 Apr; 30(4-5):463-478. PubMed ID: 38253528
[TBL] [Abstract][Full Text] [Related]
40. Robustness and pragmatism of the evidence supporting the European Society for Medical Oncology guidelines for the diagnosis, treatment, and follow-up of follicular lymphoma.
Sorigue M; Kuittinen O
Expert Rev Hematol; 2021 Jul; 14(7):655-668. PubMed ID: 34128764
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
